Recursion Pharmaceuticals (RXRX) Competitors

Recursion Pharmaceuticals logo
$2.52 -0.20 (-7.17%)
As of 02:58 PM Eastern
This is a fair market value price provided by Massive. Learn more.

RXRX vs. CRSP, ABVX, ALKS, CYTK, and RYTM

Should you buy Recursion Pharmaceuticals stock or one of its competitors? Recursion Pharmaceuticals's main competitors and comparable companies include CRISPR Therapeutics (CRSP), Abivax (ABVX), Alkermes (ALKS), Cytokinetics (CYTK), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Recursion Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Recursion Pharmaceuticals has a net margin of -697.15% compared to CRISPR Therapeutics' net margin of -1,812.07%. CRISPR Therapeutics' return on equity of -25.59% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,812.07% -25.59% -17.89%
Recursion Pharmaceuticals -697.15%-47.85%-36.26%

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 9 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.64 beat Recursion Pharmaceuticals' score of 0.01 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

CRISPR Therapeutics has higher earnings, but lower revenue than Recursion Pharmaceuticals. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$3.51M1,087.26-$581.60M-$4.74N/A
Recursion Pharmaceuticals$74.68M21.22-$644.76M-$0.90N/A

CRISPR Therapeutics presently has a consensus target price of $72.93, indicating a potential upside of 85.37%. Recursion Pharmaceuticals has a consensus target price of $7.52, indicating a potential upside of 195.48%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than CRISPR Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
1 Sell rating(s)
6 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.65
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

CRISPR Therapeutics has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market.

Summary

CRISPR Therapeutics beats Recursion Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Abivax?

Abivax (NASDAQ:ABVX) and Recursion Pharmaceuticals (NASDAQ:RXRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

Abivax has higher earnings, but lower revenue than Recursion Pharmaceuticals. Abivax is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AbivaxN/AN/A-$380.27M-$6.06N/A
Recursion Pharmaceuticals$74.68M21.22-$644.76M-$0.90N/A

Abivax has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Recursion Pharmaceuticals has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

47.9% of Abivax shares are held by institutional investors. Comparatively, 89.1% of Recursion Pharmaceuticals shares are held by institutional investors. 6.7% of Recursion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Recursion Pharmaceuticals had 13 more articles in the media than Abivax. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 4 mentions for Abivax. Abivax's average media sentiment score of 1.08 beat Recursion Pharmaceuticals' score of 0.01 indicating that Abivax is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Abivax
2 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral

Abivax currently has a consensus price target of $155.00, indicating a potential upside of 107.39%. Recursion Pharmaceuticals has a consensus price target of $7.52, indicating a potential upside of 195.48%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20

Abivax has a net margin of 0.00% compared to Recursion Pharmaceuticals' net margin of -697.15%. Recursion Pharmaceuticals' return on equity of -47.85% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
AbivaxN/A -91.69% -71.96%
Recursion Pharmaceuticals -697.15%-47.85%-36.26%

Summary

Recursion Pharmaceuticals beats Abivax on 9 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Alkermes?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Alkermes (NASDAQ:ALKS) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, media sentiment, dividends and valuation.

Recursion Pharmaceuticals has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market. Comparatively, Alkermes has a beta of 0.32, suggesting that its stock price is 68% less volatile than the broader market.

Recursion Pharmaceuticals presently has a consensus target price of $7.52, suggesting a potential upside of 195.48%. Alkermes has a consensus target price of $55.73, suggesting a potential upside of 20.95%. Given Recursion Pharmaceuticals' higher probable upside, equities research analysts plainly believe Recursion Pharmaceuticals is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65

Alkermes has higher revenue and earnings than Recursion Pharmaceuticals. Alkermes is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M21.22-$644.76M-$0.90N/A
Alkermes$1.48B5.25$241.66M-$0.02N/A

In the previous week, Recursion Pharmaceuticals had 13 more articles in the media than Alkermes. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 4 mentions for Alkermes. Alkermes' average media sentiment score of 0.04 beat Recursion Pharmaceuticals' score of 0.01 indicating that Alkermes is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Alkermes
1 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Alkermes has a net margin of -0.02% compared to Recursion Pharmaceuticals' net margin of -697.15%. Alkermes' return on equity of 0.40% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-697.15% -47.85% -36.26%
Alkermes -0.02%0.40%0.19%

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. Comparatively, 95.2% of Alkermes shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 4.6% of Alkermes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Alkermes beats Recursion Pharmaceuticals on 11 of the 17 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Cytokinetics?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Cytokinetics (NASDAQ:CYTK) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, institutional ownership, profitability, valuation, dividends, earnings and risk.

Recursion Pharmaceuticals has a beta of 1.15, suggesting that its share price is 15% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, suggesting that its share price is 55% less volatile than the broader market.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by company insiders. Comparatively, 2.6% of Cytokinetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cytokinetics has a net margin of -686.63% compared to Recursion Pharmaceuticals' net margin of -697.15%. Cytokinetics' return on equity of 0.00% beat Recursion Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-697.15% -47.85% -36.26%
Cytokinetics -686.63%N/A -48.26%

Recursion Pharmaceuticals presently has a consensus target price of $7.52, suggesting a potential upside of 195.48%. Cytokinetics has a consensus target price of $106.67, suggesting a potential upside of 105.90%. Given Recursion Pharmaceuticals' higher probable upside, equities analysts plainly believe Recursion Pharmaceuticals is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Recursion Pharmaceuticals has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M21.22-$644.76M-$0.90N/A
Cytokinetics$88.04M81.97-$784.96M-$6.04N/A

In the previous week, Recursion Pharmaceuticals had 2 more articles in the media than Cytokinetics. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 15 mentions for Cytokinetics. Cytokinetics' average media sentiment score of 0.24 beat Recursion Pharmaceuticals' score of 0.01 indicating that Cytokinetics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cytokinetics
5 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Neutral

Summary

Recursion Pharmaceuticals beats Cytokinetics on 9 of the 16 factors compared between the two stocks.

How does Recursion Pharmaceuticals compare to Rhythm Pharmaceuticals?

Recursion Pharmaceuticals (NASDAQ:RXRX) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings.

89.1% of Recursion Pharmaceuticals shares are owned by institutional investors. 6.7% of Recursion Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Recursion Pharmaceuticals has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

In the previous week, Recursion Pharmaceuticals had 4 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 17 mentions for Recursion Pharmaceuticals and 13 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.39 beat Recursion Pharmaceuticals' score of 0.01 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Recursion Pharmaceuticals
2 Very Positive mention(s)
3 Positive mention(s)
5 Neutral mention(s)
5 Negative mention(s)
0 Very Negative mention(s)
Neutral
Rhythm Pharmaceuticals
4 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Recursion Pharmaceuticals currently has a consensus target price of $7.52, indicating a potential upside of 195.48%. Rhythm Pharmaceuticals has a consensus target price of $141.67, indicating a potential upside of 25.27%. Given Recursion Pharmaceuticals' higher possible upside, analysts plainly believe Recursion Pharmaceuticals is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Recursion Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.20
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77

Rhythm Pharmaceuticals has a net margin of -69.03% compared to Recursion Pharmaceuticals' net margin of -697.15%. Recursion Pharmaceuticals' return on equity of -47.85% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Recursion Pharmaceuticals-697.15% -47.85% -36.26%
Rhythm Pharmaceuticals -69.03%-171.16%-43.00%

Rhythm Pharmaceuticals has higher revenue and earnings than Recursion Pharmaceuticals. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Recursion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Recursion Pharmaceuticals$74.68M21.22-$644.76M-$0.90N/A
Rhythm Pharmaceuticals$189.76M41.32-$196.54M-$2.90N/A

Summary

Recursion Pharmaceuticals and Rhythm Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Recursion Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RXRX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RXRX vs. The Competition

MetricRecursion PharmaceuticalsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.57B$3.95B$7.48B$11.08B
Dividend YieldN/A3.64%2.48%4.74%
P/E Ratio-2.7923.6732.6428.89
Price / Sales21.0615.438.065.36
Price / CashN/A22.6520.7221.66
Price / Book1.744.174.343.55
Net Income-$644.76M-$23.99M$3.50B$394.12M
7 Day Performance-20.60%-8.63%-7.22%-7.85%
1 Month Performance-31.01%-12.50%-9.70%-11.02%
1 Year Performance-34.42%-5.51%-2.19%-8.61%

Recursion Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RXRX
Recursion Pharmaceuticals
3.1188 of 5 stars
$2.53
-7.2%
$7.52
+197.8%
-32.5%$1.57B$74.68MN/A600
CRSP
CRISPR Therapeutics
2.8783 of 5 stars
$42.24
-0.9%
$72.93
+72.7%
-23.3%$4.13B$3.51MN/A393
ABVX
Abivax
3.3916 of 5 stars
$87.58
-2.9%
$155.00
+77.0%
-28.6%$7.90BN/AN/A98
ALKS
Alkermes
2.1491 of 5 stars
$47.03
+0.1%
$55.73
+18.5%
+61.0%$7.89B$1.48BN/A2,050
CYTK
Cytokinetics
2.7766 of 5 stars
$56.13
-0.1%
$106.67
+90.0%
-20.6%$7.82B$88.04MN/A673

Related Companies and Tools


This page (NASDAQ:RXRX) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners